1.Analysis of eight cases of acute phosphorus oxychloride poisoning.
Fanfan YI ; Wenwei CHENG ; Yugui HAO
Chinese Journal of Industrial Hygiene and Occupational Diseases 2014;32(7):546-547
Acute Disease
;
Adult
;
Female
;
Humans
;
Male
;
Middle Aged
;
Phosphorus Compounds
;
poisoning
;
Retrospective Studies
2.The efficacy and safety of continuous erythropoietin receptor activator in dialytic patients with chronic renal anemia: an open, randomized, controlled, multi-center trial
Nan GHEN ; Jiaqi QIAN ; Changlin MEI ; Aihua ZHANG ; Changying XING ; Li WANG ; Wenhu LIU ; Mei WANG ; Jianghua CHEN ; Bicheng LIU ; Fanfan HOU ; Xiangmei CHEN ; Li ZUO ; Wei SHI ; Lingbo YU ; Yi ZHANG
Chinese Journal of Internal Medicine 2012;51(7):502-507
Objective To evaluate the efficacy and safety of continuous erythropoietin receptor activator (C.E.R.A.) once every 4 weeks by subcutaneous administration on hemoglobin (Hb)maintenance in dialytic patients with chronic renal anemia who had been treated with stable dose of erythropoietin (EPO).Methods This was an open,randomized,controlled,multi-center trial.All the hemodialysis or peritoneal dialytic patients in EPO maintenance treatment received subcutaneous EPO-β during the 6-week pre-treatment period to maintain Hb level between 100 g/L and 120 g/L.Eligible patients were randomized (2∶1 ) to accept either C.E.R.A.once every 4 weeks by subcutaneous administration ( C.E.R.A.group,n =187 ) or subcutaneous EPO-β 1-3 times weekly ( EPO group,n =94) for 28 weeks (including 20-week dose titration period and 8-week efficacy evaluation period ). The starting dose of C.E.R.A.was converted according to the dose of EPO-β administered in the week preceding the first study drug administration.The primary outcome was the change of Hb level between the baseline and that in the efficacy evaluation period.Results Totally 253 patients completed the whole 28-week treatment.The change of baseline-adjusted mean Hb was +2.57 g/L for C.E.R.A.group and + 1.23 g/L for EPO group,resulting in a treatment difference of 1.34 g/L (95% CI - 1.11-3.78 g/L).Since the lower limit of 95% CI was greater than the pre-defined non-inferiority margin -7.5 g/L( P < 0.0001 ),C.E.R.A.once every 4 weeks by subcutaneous administration was clinically non-inferior to EPO regarding the maintenance of stable Hb level.The proportion of patients maintaining Hb level within the range of 100-120 g/L through efficacy evaluation period was similar between the two groups ( 69.0% for C.E.R.A.group vs 68.9% for EPO group,P >0.05 ).The overall incidence of adverse events was similar between the C.E.R.A.(41.7%)and EPO (46.2% ) groups ( P > 0.05 ).The safety findings were in accordance with the patients' primary diseases rather than the administration.Conclusions Conversion from EPO to C.E.R.A.once every 4 weeks by subcutaneous injection could maintain the Hb in target level in dialytic patients with renal anemia,and it was non-inferior to EPO.In general,subcutaneous administration of C.E.R.A.is well tolerated in dialytic patients with chronic renal anemia.
3. Changes of immunoglobulins and CD series in patients with Graves′ orbitopathy treated with high-dose methylprednisolone
Abudukerimu BUATIKAMU ; Qin LI ; Ningjian WANG ; Fangzhen XIA ; Yi CHEN ; Xiaoman CHEN ; Chunfang ZHU ; Jie QIAO ; Fanfan ZHU ; Yingli LU
Chinese Journal of Endocrinology and Metabolism 2019;35(9):756-760
Objective:
To study the effect of high-dose methylprednisolone intravenous pulse therapy on immunoglobulins and CD series in patients with active moderate-to-severe Graves′ orbitopathy.
Methods:
Twenty-seven patients with active moderate-to-severe Graves′ orbitopathy were enrolled in this study. All the patients received iv methylprednisolone pulse therapy for 12 weeks according to the 2016 European Thyroid Association/European Group on Graves′Orbitopathy(EUGOGO) Guidelines. Serum thyroidal autoantibodies, such as thyroid-stimulating hormone receptor antibody (TRAb), anti-thyroperoxidase antibody (TPOAb), and serum immunoglobulins, such as IgG, IgE, IgA, IgM were evaluated at the baseline, at the end of 4th and 12th week. Percentages of CD3+ T cells, CD4+ T cells, CD8+ T cells and CD19+ B cells, CD16+ or CD56+ NK cells were also evaluated at each time point.
Results:
TRAb, TPOA and IgE, IgG, IgA were significantly decreased both after 4th week and after 12th week (all